{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:32:17Z","timestamp":1793424737864,"version":"4.5.0"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,6,13]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Some patients with neovascular age-related macular degeneration (nAMD) have persistent signs of exudation under treatment with intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents. We examined the real-world anatomical responses among patients with suboptimal response and switched to faricimab using artificial intelligence (AI)-based retinal fluid quantification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, multicentric, cohort study of patients in France with exudative signs and switched to faricimab without a new loading phase, maintaining the same prior injection interval. The RetInSight Fluid Monitor AI software quantified subretinal (SRF) and intraretinal (IRF) fluid on spectral domain optical coherence tomography. The primary outcome was change in SRF and IRF volumes in the central 1 and 6\u2009mm retinal areas after one and two injections of faricimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      74 patients (74 eyes) were included (mean age: 81.5\u00b18.4 years, 49% male). Significant reductions were observed in mean 1\u2009mm IRF (\u22122.9\u00b118.3\u2009nl; p=0.002), mean 6\u2009mm IRF (\u221217.7\u00b171.1\u2009nl; p&lt;0.001) and mean 6\u2009mm SRF (\u221224.8\u00b1156.3\u2009nl; p&lt;0.001) volumes after one injection. The proportion of dry eyes (&lt;5\u2009nl for SRF and IRF in the 1 and 6\u2009mm areas) increased from 0% at baseline to 32.4% after one injection and 48.4% after two injections. Lower baseline SRF volumes were predictive of dry response after one injection (\n                      <jats:sub>adj<\/jats:sub>\n                      OR 0.965; p=0.028) and lower baseline IRF volumes were predictive of dry response after two injections (\n                      <jats:sub>adj<\/jats:sub>\n                      OR 0.373; p=0.051).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nearly half of patients achieved a dry response after two injections. AI-assisted fluid quantification provided objective monitoring, identifying lower baseline SRF and IRF as predictive factors for good response. Limited patient inclusion means longer-term and larger prospective studies are now required using automated retinal fluid quantification to further refine the baseline characteristics of good switch responders to better adapt switch protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002267","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T14:15:24Z","timestamp":1750688124000},"page":"e002267","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world faricimab switch in France: artificial intelligence-based detection of changes in exudative signs in difficult-to-treat neovascular age-related macular degeneration"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3941-1304","authenticated-orcid":false,"given":"Vincent","family":"Gualino","sequence":"first","affiliation":[{"name":"Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France"},{"name":"Clinique Honor\u00e9 Cave, Montauban, France"},{"name":"Ophthalmology Department, Lariboisi\u00e8re Hospital, Paris University Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Sohier","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France"},{"name":"Clinique Honor\u00e9 Cave, Montauban, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Sibert","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Dijon University Hospital, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Erginay","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Lariboisi\u00e8re Hospital, Paris University Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Varenne","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3928-5688","authenticated-orcid":false,"given":"Jacqueline","family":"Butterworth","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8549-7455","authenticated-orcid":false,"given":"Aude","family":"Couturier","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Lariboisi\u00e8re Hospital, Paris University Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Henry","family":"Gabrielle","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Dijon University Hospital, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3837-0619","authenticated-orcid":false,"given":"Vincent","family":"Soler","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, Toulouse, France"},{"name":"Faculty of Medicine, University of Toulouse III, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Creuzot-Garcher","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Dijon University Hospital, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2026010721205618000_10.1.e002267.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.036"},{"key":"2026010721205618000_10.1.e002267.2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"The Lancet"},{"key":"2026010721205618000_10.1.e002267.3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.oret.2024.01.004","article-title":"European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice: Data from the Fight Retinal Blindness! Registry","volume":"8","author":"Boudousq","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"2026010721205618000_10.1.e002267.4","doi-asserted-by":"crossref","DOI":"10.3390\/cells8050471","article-title":"Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology","volume":"8","author":"Akwii","year":"2019","journal-title":"Cells"},{"key":"2026010721205618000_10.1.e002267.5","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081869","article-title":"Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab","volume":"9","author":"Khan","year":"2020","journal-title":"Cells"},{"key":"2026010721205618000_10.1.e002267.6","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100076","article-title":"TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration","volume":"1","author":"Khanani","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"2026010721205618000_10.1.e002267.7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"The Lancet"},{"key":"2026010721205618000_10.1.e002267.8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","article-title":"Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME","volume":"10","author":"Penha","year":"2024","journal-title":"Int J Retin Vitr"},{"key":"2026010721205618000_10.1.e002267.9","doi-asserted-by":"publisher","DOI":"10.3928\/15428877-20110627-05"},{"key":"2026010721205618000_10.1.e002267.10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/eye.2016.227","article-title":"A view of the current and future role of optical coherence tomography in the management of age-related macular degeneration","volume":"31","author":"Schmidt-Erfurth","year":"2017","journal-title":"Eye (Lond)"},{"key":"2026010721205618000_10.1.e002267.11","doi-asserted-by":"crossref","DOI":"10.1007\/s10792-024-03297-1","article-title":"Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration","volume":"44","author":"Aldhanhani","year":"2024","journal-title":"Int Ophthalmol"},{"key":"2026010721205618000_10.1.e002267.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02553-5"},{"key":"2026010721205618000_10.1.e002267.13","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00417-024-06421-0","article-title":"Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration","volume":"262","author":"Schneider","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721205618000_10.1.e002267.14","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3390\/bioengineering11050478","article-title":"Real-World Weekly Efficacy Analysis of Faricimab in Patients with Age-Related Macular Degeneration","volume":"11","author":"Muth","year":"2024","journal-title":"Bioengineering (Basel)"},{"key":"2026010721205618000_10.1.e002267.15","doi-asserted-by":"crossref","first-page":"1346322","DOI":"10.3389\/fopht.2023.1346322","article-title":"Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population","volume":"3","author":"Ibrahim","year":"2023","journal-title":"Front Ophthalmol"},{"key":"2026010721205618000_10.1.e002267.16","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.2147\/OPTH.S483563","article-title":"Outcomes After Switching to Faricimab for Refractive Macular Edema in Treatment-Experienced Eyes with Neovascular Age-Related Macular Degeneration","volume":"18","author":"Qaseem","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"2026010721205618000_10.1.e002267.17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/IAE.0000000000004322","article-title":"REAL-WORLD LONG-TERM OUTCOMES OF INTRAVITREAL FARICIMAB IN PREVIOUSLY TREATED CHRONIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION","volume":"45","author":"Ambati","year":"2025","journal-title":"Retina (Philadelphia, Pa)"},{"key":"2026010721205618000_10.1.e002267.18","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.2147\/OPTH.S482948","article-title":"Real-World-Data of Treatment-Na\u00efve and Previously Treated Patients Receiving Up to 3 Injections of Faricimab in Neovascular Age-Related Macular Degeneration","volume":"18","author":"Kunzmann","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"2026010721205618000_10.1.e002267.19","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","article-title":"Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic","volume":"37","author":"Stanga","year":"2023","journal-title":"Eye (Lond)"},{"key":"2026010721205618000_10.1.e002267.20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","article-title":"Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy","volume":"38","author":"Goodchild","year":"2024","journal-title":"Eye (Lond)"},{"key":"2026010721205618000_10.1.e002267.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.10.031"},{"key":"2026010721205618000_10.1.e002267.22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/aos.16799","article-title":"Correlation of retinal fluid and photoreceptor and RPE loss in neovascular AMD by automated quantification, a real-world FRB! analysis","volume":"103","author":"Mares","year":"2025","journal-title":"Acta Ophthalmol"},{"key":"2026010721205618000_10.1.e002267.23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1055\/a-2378-6138","article-title":"Role of Artificial Intelligence in Retinal Diseases","volume":"241","author":"Mai","year":"2024","journal-title":"Klin Monbl Augenheilkd"},{"key":"2026010721205618000_10.1.e002267.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100972"},{"key":"2026010721205618000_10.1.e002267.25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0000000000003385","article-title":"SYSTEMATIC CORRELATION OF CENTRAL SUBFIELD THICKNESS WITH RETINAL FLUID VOLUMES QUANTIFIED BY DEEP LEARNING IN THE MAJOR EXUDATIVE MACULAR DISEASES","volume":"42","author":"Pawloff","year":"2022","journal-title":"Retina (Philadelphia, Pa)"},{"key":"2026010721205618000_10.1.e002267.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2016.12.009"},{"key":"2026010721205618000_10.1.e002267.27","unstructured":"Vabysmo R . Switzerland summary of product characteristics for faricimab."},{"key":"2026010721205618000_10.1.e002267.28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jfo.2019.11.002","article-title":"Avis d\u2019experts : actualisation des bonnes pratiques des injections intravitr\u00e9ennes. Recommandations de la Soci\u00e9t\u00e9 fran\u00e7aise d\u2019ophtalmologie et de la Soci\u00e9t\u00e9 fran\u00e7aise d\u2019hygi\u00e8ne hospitali\u00e8re","volume":"43","author":"Cohen","year":"2020","journal-title":"Journal Fran\u00e7ais d\u2019Ophtalmologie"},{"key":"2026010721205618000_10.1.e002267.29","doi-asserted-by":"crossref","unstructured":"Khodor A , Choi S , Nanda T , et al . Visual and Anatomic Responses in Patients With Neovascular Age-Related Macular Degeneration and a Suboptimal Response to Anti-VEGF Therapy Switched to Faricimab. J Vitreoretin Dis 2024:24741264241271649. doi:10.1177\/24741264241271649","DOI":"10.1177\/24741264241271649"},{"key":"2026010721205618000_10.1.e002267.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06222-x"},{"key":"2026010721205618000_10.1.e002267.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2024-001967","article-title":"Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations","volume":"10","author":"Wong","year":"2025","journal-title":"BMJ Open Ophthalmol"},{"key":"2026010721205618000_10.1.e002267.32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajo.2024.08.008","article-title":"Severe Intraocular Inflammation After Intravitreal Injection of Faricimab: A Single-Site Case Series of Six Patients","volume":"269","author":"Ben Ghezala","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"2026010721205618000_10.1.e002267.33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2019-000307","article-title":"Treatment failure in neovascular age-related macular degeneration is associated with a complex chemokine receptor profile","volume":"4","author":"Bjerregaard","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"2026010721205618000_10.1.e002267.34","article-title":"Quantifying Fluid and Function in Suboptimal Responders Switched From an Anti-vascular Endothelial Growth Factor (VEGF) to Faricimab","volume":"16","author":"Sutter","year":"2024","journal-title":"Cureus"},{"key":"2026010721205618000_10.1.e002267.35","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41433-024-03532-0","article-title":"Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study","volume":"39","author":"Aziz","year":"2025","journal-title":"Eye (Lond)"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:21:58Z","timestamp":1767849718000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjophth-2025-002267"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002267","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}